Female Contraception - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Female Contraception - Pipeline Review, H1 2018’, provides an overview of the Female Contraception pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Female Contraception

- The report reviews pipeline therapeutics for Female Contraception by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Female Contraception therapeutics and enlists all their major and minor projects

- The report assesses Female Contraception therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Female Contraception

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Female Contraception

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Female Contraception pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Agile Therapeutics Inc

Bayer AG

Evofem Biosciences Inc

Hervana Ltd

MedinCell SA

Mithra Pharmaceuticals SA

Orbis Biosciences Inc

Teva Pharmaceutical Industries Ltd

Viramal Ltd

Agile Therapeutics Inc

Bayer AG

Evofem Biosciences Inc

Hervana Ltd

MedinCell SA

Mithra Pharmaceuticals SA

Orbis Biosciences Inc

Teva Pharmaceutical Industries Ltd

Viramal Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Contraception – Overview

Female Contraception – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Contraception – Overview

Female Contraception – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Female Contraception – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Contraception – Companies Involved in Therapeutics Development

Agile Therapeutics Inc

Bayer AG

Evofem Biosciences Inc

Hervana Ltd

MedinCell SA

Mithra Pharmaceuticals SA

Orbis Biosciences Inc

Teva Pharmaceutical Industries Ltd

Viramal Ltd

Female Contraception – Drug Profiles

(anastrozole + levonorgestrel) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(dienogest + ethinyl estradiol) PR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(drospirenone + estetrol) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(estradiol + segesterone acetate) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ethinylestradiol + segesterone acetate) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-200 ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-200 SP – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-20015 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-890 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphora – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

drospirenone – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Female Contraception – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-317 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-508 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-625 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etonogestrel – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etonogestrel ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-102 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDC-WWM – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugates for Female Contraception – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-1003 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OB-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPCM – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-003296 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Female Contraception – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Progesterone Receptor for Female Contraception – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Female Contraception – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TV-46046 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Female Contraception – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Contraception – Dormant Projects

Female Contraception – Discontinued Products

Female Contraception – Product Development Milestones

Featured News & Press Releases

May 03, 2018: Mithra Announces Last Subject Visit in Estelle Phase III Study in EU/Russia and Completion of Endometrial Substudy

Mar 28, 2018: Mithra Applies For Additional Estelle Patent Based On Positive Hemostasis Data

Mar 23, 2018: Mithra Announces Completion of Estelle Cycles Required In Phase Iii Contraception Studies

Jan 23, 2018: Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019

Jan 03, 2018: Population Councils One-Year Contraceptive Ring Advances to FDA Review

Dec 07, 2017: MedinCell receives grant to develop long-acting injectable contraceptive

Nov 30, 2017: Mithra Provides Update On Estelle Study

Oct 30, 2017: Mithra Completes Recruitment for Estelle Phase III Study in US & Canada

Oct 30, 2017: Mithra Completes Recruitment for Estelle Phase III Study in US and Canada

Aug 18, 2017: Mithra Announces First Subject Completes Estelle Phase III Study

Aug 09, 2017: Mithra Pharmaceuticals: Recruitment Completed in Estelle Population PK Sub study

Jul 27, 2017: Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA for Prevention of Pregnancy

Jun 26, 2017: Estelle Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal

May 12, 2017: Mithra to Initiate PK Study for Estelle

Feb 07, 2017: Mithra Completes Recruitment For European Phase III Estelle Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Female Contraception, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Tables

Number of Products under Development for Female Contraception, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Female Contraception – Pipeline by Agile Therapeutics Inc, H1 2018

Female Contraception – Pipeline by Bayer AG, H1 2018

Female Contraception – Pipeline by Evofem Biosciences Inc, H1 2018

Female Contraception – Pipeline by Hervana Ltd, H1 2018

Female Contraception – Pipeline by MedinCell SA, H1 2018

Female Contraception – Pipeline by Mithra Pharmaceuticals SA, H1 2018

Female Contraception – Pipeline by Orbis Biosciences Inc, H1 2018

Female Contraception – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018

Female Contraception – Pipeline by Viramal Ltd, H1 2018

Female Contraception – Dormant Projects, H1 2018

Female Contraception – Dormant Projects, H1 2018 (Contd..1), H1 2018

Female Contraception – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Female Contraception, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Female Contraception, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports